The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health officials seek newer information on vaccine results in the global fight against ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes albopictus. It is a ...

"FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq," the release reads. "While the safety of Ixchiq for use in individuals 60 years of age and older is being ...

“While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, the FDA and CDC are recommending a pause in the use of the vaccine in this age group ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events. Two ...

Chikungunya is a mosquito-borne tropical disease that causes intense joint pain and fever. Although it is rare in the U.S., about 100 to 200 cases are reported annually, mostly among Americans ...

Due to an ongoing investigation of serious adverse events, it is recommended that the use of Ixchiq ® (chikungunya ... for Disease Control and Prevention (CDC). According to the Agencies, as ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...